Cargando…
Apolipoprotein E, amyloid-ß clearance and therapeutic opportunities in Alzheimer's disease
Alzheimer's disease (AD) is a progressive neurodegenerative disease characterised by extracellular amyloid-ß (Aß) and intraneuronal tau protein brain pathologies. The most significant risk factor for non-familial AD is the presence of the E4 isoform of the cholesterol transporter apolipoprotein...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3506946/ https://www.ncbi.nlm.nih.gov/pubmed/22929359 http://dx.doi.org/10.1186/alzrt135 |
_version_ | 1782250986035740672 |
---|---|
author | Kline, Adam |
author_facet | Kline, Adam |
author_sort | Kline, Adam |
collection | PubMed |
description | Alzheimer's disease (AD) is a progressive neurodegenerative disease characterised by extracellular amyloid-ß (Aß) and intraneuronal tau protein brain pathologies. The most significant risk factor for non-familial AD is the presence of the E4 isoform of the cholesterol transporter apolipoprotein E (apoE). Despite extensive basic research, the exact role of apoE in disease aetiology remains unclear. Correspondingly, therapeutic targeting of apoE in AD is at an early preclinical stage. In this review, I discuss the key interactions of apoE and Aß pathology, the current progress of preclinical animal models and the caveats of existing therapeutic approaches targeting apoE. Finally, novel Alzheimer's genetics and Aß-independent disease mechanisms are highlighted. |
format | Online Article Text |
id | pubmed-3506946 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35069462013-02-27 Apolipoprotein E, amyloid-ß clearance and therapeutic opportunities in Alzheimer's disease Kline, Adam Alzheimers Res Ther Review Alzheimer's disease (AD) is a progressive neurodegenerative disease characterised by extracellular amyloid-ß (Aß) and intraneuronal tau protein brain pathologies. The most significant risk factor for non-familial AD is the presence of the E4 isoform of the cholesterol transporter apolipoprotein E (apoE). Despite extensive basic research, the exact role of apoE in disease aetiology remains unclear. Correspondingly, therapeutic targeting of apoE in AD is at an early preclinical stage. In this review, I discuss the key interactions of apoE and Aß pathology, the current progress of preclinical animal models and the caveats of existing therapeutic approaches targeting apoE. Finally, novel Alzheimer's genetics and Aß-independent disease mechanisms are highlighted. BioMed Central 2012-08-27 /pmc/articles/PMC3506946/ /pubmed/22929359 http://dx.doi.org/10.1186/alzrt135 Text en Copyright ©2012 BioMed Central Ltd |
spellingShingle | Review Kline, Adam Apolipoprotein E, amyloid-ß clearance and therapeutic opportunities in Alzheimer's disease |
title | Apolipoprotein E, amyloid-ß clearance and therapeutic opportunities in Alzheimer's disease |
title_full | Apolipoprotein E, amyloid-ß clearance and therapeutic opportunities in Alzheimer's disease |
title_fullStr | Apolipoprotein E, amyloid-ß clearance and therapeutic opportunities in Alzheimer's disease |
title_full_unstemmed | Apolipoprotein E, amyloid-ß clearance and therapeutic opportunities in Alzheimer's disease |
title_short | Apolipoprotein E, amyloid-ß clearance and therapeutic opportunities in Alzheimer's disease |
title_sort | apolipoprotein e, amyloid-ß clearance and therapeutic opportunities in alzheimer's disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3506946/ https://www.ncbi.nlm.nih.gov/pubmed/22929359 http://dx.doi.org/10.1186/alzrt135 |
work_keys_str_mv | AT klineadam apolipoproteineamyloidßclearanceandtherapeuticopportunitiesinalzheimersdisease |